Chikdu S. Shivalila
Massachusetts Institute of Technology
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Chikdu S. Shivalila.
Cell | 2013
Hui Yang; Haoyi Wang; Chikdu S. Shivalila; Albert W. Cheng; Linyu Shi; Rudolf Jaenisch
The type II bacterial CRISPR/Cas system is a novel genome-engineering technology with the ease of multiplexed gene targeting. Here, we created reporter and conditional mutant mice by coinjection of zygotes with Cas9 mRNA and different guide RNAs (sgRNAs) as well as DNA vectors of different sizes. Using this one-step procedure we generated mice carrying a tag or a fluorescent reporter construct in the Nanog, the Sox2, and the Oct4 gene as well as Mecp2 conditional mutant mice. In addition, using sgRNAs targeting two separate sites in the Mecp2 gene, we produced mice harboring the predicted deletions of about 700 bps. Finally, we analyzed potential off-targets of five sgRNAs in gene-modified mice and ESC lines and identified off-target mutations in only rare instances.
Cell Research | 2013
Albert W. Cheng; Haoyi Wang; Hui Yang; Linyu Shi; Yarden Katz; Thorold W. Theunissen; Sudharshan Rangarajan; Chikdu S. Shivalila; Daniel Benjamin Dadon; Rudolf Jaenisch
Technologies allowing for specific regulation of endogenous genes are valuable for the study of gene functions and have great potential in therapeutics. We created the CRISPR-on system, a two-component transcriptional activator consisting of a nuclease-dead Cas9 (dCas9) protein fused with a transcriptional activation domain and single guide RNAs (sgRNAs) with complementary sequence to gene promoters. We demonstrate that CRISPR-on can efficiently activate exogenous reporter genes in both human and mouse cells in a tunable manner. In addition, we show that robust reporter gene activation in vivo can be achieved by injecting the system components into mouse zygotes. Furthermore, we show that CRISPR-on can activate the endogenous IL1RN, SOX2, and OCT4 genes. The most efficient gene activation was achieved by clusters of 3-4 sgRNAs binding to the proximal promoters, suggesting their synergistic action in gene induction. Significantly, when sgRNAs targeting multiple genes were simultaneously introduced into cells, robust multiplexed endogenous gene activation was achieved. Genome-wide expression profiling demonstrated high specificity of the system.
Cell | 2015
Yonatan Stelzer; Chikdu S. Shivalila; Frank Soldner; Styliani Markoulaki; Rudolf Jaenisch
Mammalian DNA methylation plays an essential role in development. To date, only snapshots of different mouse and human cell types have been generated, providing a static view on DNA methylation. To enable monitoring of methylation status as it changes over time, we establish a reporter of genomic methylation (RGM) that relies on a minimal imprinted gene promoter driving a fluorescent protein. We show that insertion of RGM proximal to promoter-associated CpG islands reports the gain or loss of DNA methylation. We further utilized RGM to report endogenous methylation dynamics of non-coding regulatory elements, such as the pluripotency-specific super enhancers of Sox2 and miR290. Loci-specific DNA methylation changes and their correlation with transcription were visualized during cell-state transition following differentiation of mouse embryonic stem cells and during reprogramming of somatic cells to pluripotency. RGM will allow the investigation of dynamic methylation changes during development and disease at single-cell resolution.
Stem cell reports | 2017
Raghu Ram Edupuganti; Arigela Harikumar; Yair Aaronson; Alva Biran; Badi Sri Sailaja; Malka Nissim-Rafinia; Gajendra Kumar Azad; Malkiel A. Cohen; Jung Eun Park; Chikdu S. Shivalila; Styliani Markoulaki; Siu Kwan Sze; Rudolf Jaenisch; Eran Meshorer
Summary Embryonic stem cells (ESCs) are regulated by pluripotency-related transcription factors in concert with chromatin regulators. To identify additional stem cell regulators, we screened a library of endogenously labeled fluorescent fusion proteins in mouse ESCs for fluorescence loss during differentiation. We identified SET, which displayed a rapid isoform shift during early differentiation from the predominant isoform in ESCs, SETα, to the primary isoform in differentiated cells, SETβ, through alternative promoters. SETα is selectively bound and regulated by pluripotency factors. SET depletion causes proliferation slowdown and perturbed neuronal differentiation in vitro and developmental arrest in vivo, and photobleaching methods demonstrate SETs role in maintaining a dynamic chromatin state in ESCs. This work identifies an important regulator of pluripotency and early differentiation, which is controlled by alternative promoter usage.
bioRxiv | 2018
Reinhard Roessler; Johanna Goldmann; Chikdu S. Shivalila; Rudolf Jaenisch
Molecular and cellular profiling of patient-specific neural cell types provides suggestions for the involvement of JIP2 in the neurodevelopmental disorder Phelan–McDermid syndrome. Phelan–McDermid syndrome (also known as 22q13.3 deletion syndrome) is a syndromic form of autism spectrum disorder and currently thought to be caused by heterozygous loss of SHANK3. However, patients most frequently present with large chromosomal deletions affecting several additional genes. We used human pluripotent stem cell technology and genome editing to further dissect molecular and cellular mechanisms. We found that loss of JIP2 (MAPK8IP2) may contribute to a distinct neurodevelopmental phenotype in neural progenitor cells (NPCs) affecting neuronal maturation. This is most likely due to a simultaneous down-regulation of c-Jun N-terminal kinase (JNK) proteins, leading to impaired generation of mature neurons. Furthermore, semaphorin signaling appears to be impaired in patient NPCs and neurons. Pharmacological activation of neuropilin receptor 1 (NRP1) rescued impaired semaphorin pathway activity and JNK expression in patient neurons. Our results suggest a novel disease-specific mechanism involving the JIP/JNK complex and identify NRP1 as a potential new therapeutic target.
Archive | 2014
Rudolf Jaenisch; Haoyi Wang; Hui Yang; Chikdu S. Shivalila; Wu Albert Cheng
Cell Reports | 2016
Yonatan Stelzer; Yuelin Song; Chikdu S. Shivalila; Styliani Markoulaki; Rudolf Jaenisch
PMC | 2016
Frank Soldner; Yonatan Stelzer; Brian J. Abraham; Jeanne C. Latourelle; M. Inmaculada Barrasa; Johanna Goldmann; Richard H. Myers; Richard A. Young; Rudolf Jaenisch; Chikdu S. Shivalila
PMC | 2015
Yonatan Stelzer; Frank Soldner; Styliani Markoulaki; Chikdu S. Shivalila; Rudolf Jaenisch
Archive | 2014
Rudolf Jaenisch; Haoyi Wang; Hui Yang; Chikdu S. Shivalila; Wu Albert Cheng